Our mission
The success of nanoparticles in COVID-19 mRNA vaccines has sparked a tech revolution in the biopharma sector.
Today, tens of thousands of reports describe novel therapeutic nanoparticles (e.g., lipid nanoparticles (LNPs), extracellular vesicles (EVs and exosomes), lipid vesicles (liposomes), polymer micelles, etc), many claiming to outperform their predecessors. Yet, a lack of data standardization and comparison among these studies makes it difficult to properly assess which system truly triumphs. While traditional nanoparticle standards exist and could offer some help, they are not fit for purpose as they lack the structural complexity of modern therapeutic nanoparticles.
At Vesiculate, we are on a mission to improve the accuracy of nanoparticle analysis methods and to enable data standardization through our Syncle reagents that better represent real-world nanoparticle samples.
Our vision
We envision a world where nanoparticles act as a universal platform, unlocking the full potential of therapeutic drugs and biologics to transform healthcare for the better.
Our goal is to be the first name to come to mind when researchers seek nanoparticle reagents for their work. Today, we begin with vesicles—but this is just the beginning.
About Team Vesiculate
Established in 2023, Vesiculate has a team of 3-4 employees and currently incubates within the Australian Genome Foundry (AGF) at Macquarie University (Sydney, Australia) thanks to the support of our first believers and Bioplatforms Australia. Vesiculate is further supported by UNSW Founders, having previously participated in their flagship 10x accelerator program.
Meet our Founder
Vesiculate is the brainchild of Dr. Chin Ken Wong, a former academic with over a decade of hands-on experience engineering nanoparticles (lipids, polymers, inorganics, coacervates, hybrids—you name it, he's made it!).
Ken holds a PhD in Chemistry and honed his skills through two postdoctoral spells in Australia and Germany, where he was notably an Alexander von Humboldt Fellow. Ken has a proven academic track record publishing in top-tier interdisciplinary journals including JACS, Angew. Chem, Nat. Commun, ACS Nano, Chem. Soc. Rev., and more.
Ken also currently holds an Adjunct Lecturer position at UNSW Sydney.
Our principles
Scale
We only build solutions that scale.
Impact
Innovation over competition—
we choose to build solutions that address the most challenging problems in life science.
Collaborate
We incorporate end-user demands and feedback throughout our reagent development process.
Adept
We proactively research the latest nanoparticle technologies to stay at the technical forefront.
Our capabilities
Access to chemistry and PC2 lab facilities at Macquarie University
Access to state-of-the-art analytical instrumentation to meet nanoparticle characterization demands
Transmission electron microscopy (TEM)
Scanning electron microscopy (SEM)
Cryogenic electron microscopy (Cryo-EM, including cryo-tomography and single-particle reconstruction)
Dynamic light scattering (DLS)
Multi-angle dynamic light scattering (MADLS)
Electrophoretic potential (Zeta potential)
Nanoparticle tracking analysis (NTA)
Single-particle flow cytometry (FCM)
Spectroscopy (UV-Vis, fluorescence, plate reader)
Custom vesicle formulations
Custom non-vesicle based formulations (micelles, latexes, microparticles, porous particles, etc)
Formulation advice and consulting services